Sabcomeline
![]() | |
| Clinical data | |
|---|---|
| ATC code | None |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 159912-58-0 |
| PubChem (CID) | 9577995 |
| IUPHAR/BPS | 306 |
| ChemSpider | 7852359 |
| UNII |
P8P92V596C |
| ChEMBL | CHEMBL134641 |
| Chemical and physical data | |
| Formula | C10H15N3O |
| Molar mass | 193.12 g/mol |
| 3D model (Jmol) | Interactive image |
| |
Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease.[1] It made it to phase III clinical trials before being discontinued due to poor results.
See also
References
- ↑ Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1059–68. PMID 9399977.
| AChE inhibitors | |
|---|---|
| Others | |
This article is issued from Wikipedia - version of the 9/2/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
